二甲双胍联合维格列汀治疗2型糖尿病的疗效分析(1)
[摘要] 目的 探討二甲双胍联合维格列汀治疗2型糖尿病的疗效观察。方法 方便选取2016年8月—2017年8月在该院内分泌科治疗的130例2型糖尿病患者，随机分为两组，每组65例，对照组采用二甲双胍治疗，观察组采用二甲双胍联合维格列汀治疗，比较两组患者的血糖水平、胰岛素及胰岛抵抗情况、不良反应。 结果 观察组治疗后FGB(7.02±1.04)mmol/L、2 hPG(10.32±2.16)mmol/L、HbA1c(6.72±1.13)%较对照组明显降低，差异有统计学意义(t=4.628、6.878、6.964，P<0.05)；观察组治疗后HOMA-β(60.15±10.14)、FINS(13.52±0.95)mU/L、GLP-1(82.33±18.41)pmol/L与对照组相比明显升高，而HOMA-IR(3.10±0.92)明显降低，差异有统计学意义(t=15.432、6.928、11.628、5.324，P<0.05)；两组在腹部不适、恶心呕吐、低血糖等不良反应发生率方面观察组6.15%、对照组为7.69%，差异无统计学意义(χ2=0.119，P>0.05)。结论 二甲双胍联合维格列汀治疗2型糖尿病的疗效显著，能有效控制血糖，改善胰岛素抵抗，提高胰岛β细胞功能，且不良反应轻微，具有积极的临床意义。
[关键词] 2型糖尿病；二甲双胍；维格列汀；疗效观察
[中图分类号] R587 [文献标识码] A [文章编号] 1674-0742(2018)03(a)-0112-03
Efficacy of Metformin Combined with Vildagliptin in Type 2 Diabetes Mellitus
FU Chang-ming1， CHU Ji-ying2， YAN Li-ting3
1.Pharmacy Department， Zhongshan Hospital Affiliated to Fudan University， Shanghai， 200032 China； 2.Department of Pharmacy， Sixth People’s Hospital Affiliated to Jiaotong University， Shanghai， 201100 China； 3.Pharmacy Department， the First People’s Hospital of Jiaotong University， Shanghai， 200080 China
[Abstract] Objective This paper tries to investigate the therapeutic effect of metformin in treatment of type 2 diabetes mellitus. Methods 130 cases of patients with type 2 diabetes from August 2016 to August 2017 in this hospital of endocrinology treatment were convenient selected and randomly divided into two groups， each group had 65 cases， the control group was treated with metformin， observation group with metformin in combination with Glenn treatment， compared two groups of patients with blood glucose， insulin and insulin resistance and adverse reactions. Results The observation group after treatment， FGB (7.02±1.04)mmol/L， 2 hPG(10.32±2.16)mmol/L， HbA1c(6.72±1.13)% were significantly lower than the control group， the difference was statistically significant (t=4.628， 6.878， 6.964， P<0.05)； the patients in the observation group HOMA- beta (60.15±10.14)， FINS(13.52±0.95)mU/L， GLP-1(82.33±18.41)pmol/L compared with the control group increased significantly， while the HOMA-IR (3.10 ± 0.92) was significantly lower， the difference was statistically significant (t=15.432， 6.928， 11.628， 5.324， P<0.05)； the adverse reactions of the two groups in abdominal discomfort， nausea and vomiting， hypoglycemia in observation group of 6.15% and the control group was 7.69%， the difference was not statistically significant(χ2=0.119， P>0.05). Conclusion Metformin combined with vildagliptin treatment of type 2 diabetes has significant effect， which can effectively control blood glucose， improve insulin resistance， improve pancreatic β-cell function， and mild adverse reactions， with a positive clinical significance., 百拇医药(符昌鸣 褚季颖 严莉婷)
[关键词] 2型糖尿病；二甲双胍；维格列汀；疗效观察
[中图分类号] R587 [文献标识码] A [文章编号] 1674-0742(2018)03(a)-0112-03
Efficacy of Metformin Combined with Vildagliptin in Type 2 Diabetes Mellitus
FU Chang-ming1， CHU Ji-ying2， YAN Li-ting3
1.Pharmacy Department， Zhongshan Hospital Affiliated to Fudan University， Shanghai， 200032 China； 2.Department of Pharmacy， Sixth People’s Hospital Affiliated to Jiaotong University， Shanghai， 201100 China； 3.Pharmacy Department， the First People’s Hospital of Jiaotong University， Shanghai， 200080 China
[Abstract] Objective This paper tries to investigate the therapeutic effect of metformin in treatment of type 2 diabetes mellitus. Methods 130 cases of patients with type 2 diabetes from August 2016 to August 2017 in this hospital of endocrinology treatment were convenient selected and randomly divided into two groups， each group had 65 cases， the control group was treated with metformin， observation group with metformin in combination with Glenn treatment， compared two groups of patients with blood glucose， insulin and insulin resistance and adverse reactions. Results The observation group after treatment， FGB (7.02±1.04)mmol/L， 2 hPG(10.32±2.16)mmol/L， HbA1c(6.72±1.13)% were significantly lower than the control group， the difference was statistically significant (t=4.628， 6.878， 6.964， P<0.05)； the patients in the observation group HOMA- beta (60.15±10.14)， FINS(13.52±0.95)mU/L， GLP-1(82.33±18.41)pmol/L compared with the control group increased significantly， while the HOMA-IR (3.10 ± 0.92) was significantly lower， the difference was statistically significant (t=15.432， 6.928， 11.628， 5.324， P<0.05)； the adverse reactions of the two groups in abdominal discomfort， nausea and vomiting， hypoglycemia in observation group of 6.15% and the control group was 7.69%， the difference was not statistically significant(χ2=0.119， P>0.05). Conclusion Metformin combined with vildagliptin treatment of type 2 diabetes has significant effect， which can effectively control blood glucose， improve insulin resistance， improve pancreatic β-cell function， and mild adverse reactions， with a positive clinical significance., 百拇医药(符昌鸣 褚季颖 严莉婷)